FAQs
The average price target for Cassava Sciences is $107.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $107.00 ,the lowest forecast is $107.00.
What is the price target for SAVA in 2025? ›
$105.06 ↑339.77% Estimated share price by June 12, 2025.
Is cassava a buy or sell? ›
Cassava Sciences stock has received a consensus rating of buy. The average rating score is and is based on 7 buy ratings, 0 hold ratings, and 0 sell ratings.
What is the price target for SAVA 2024? ›
Cassava Sciences Inc has a consensus price target of $75.5 based on the ratings of 4 analysts. The high is $107 issued by Rodman & Renshaw on August 8, 2024.
What is the future for cassava science? ›
Based on the Rule 16, the options market is currently suggesting that Cassava Sciences will have an average daily up or down price movement of about 13.19% per day over the life of the 2024-08-16 option contract. With Cassava Sciences trading at USD 28.51, that is roughly USD 3.76 .
Should I invest in Cassava Sciences? ›
Cassava Sciences, Inc.
may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of SAVA, demonstrate its potential to underperform the market. It currently has a Growth Score of F.
Is Sava a good stock to buy now? ›
The consensus among 2 Wall Street analysts covering (NASDAQ: SAVA) stock is to Strong Buy SAVA stock.
Why is Sava dropping? ›
NASDAQ: SAVA
The decline came on the heels of the federal indictment on Friday of Hoau-Yan Wang, a former consultant to Cassava. Wang was accused of fraud related to grant applications made to the U.S. National Institutes of Health (NIH) for work on Cassava's experimental drug simufilam.
What is the Kirkland stock price forecast for 2025? ›
The Wall Street analyst predicted that Kirkland's's share price could reach $7.00 by Jun 7, 2025. The average Kirkland's stock price prediction forecasts a potential upside of 379.45% from the current KIRK share price of $1.46.
Who owns Cassava Sciences stock? ›
Largest shareholders include BlackRock Inc., Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, State Street Corp, IWM - iShares Russell 2000 ETF, Geode Capital Management, Llc, Susquehanna International Group, Llp, Group One Trading, L.p., VEXMX - Vanguard Extended Market Index Fund ...
Cassava (Manihot esculenta) production is vital to the economy of Nigeria as the country is the world's largest producer of the commodity. The crop is produced in 24 of the country's 36 states.
What is the market potential of cassava? ›
Global Cassava Market Overview
The cassava market size was valued at USD 175.9 Billion in 2022. The cassava industry is projected to grow from USD 183.25 Billion in 2024 to USD 254.28 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.18% during the forecast period (2024 - 2032).
What is the stock price forecast for Cassava Sciences in 2025? ›
According to analysts, SAVA price target is 107.00 USD with a max estimate of 107.00 USD and a min estimate of 107.00 USD. Check if this forecast comes true in a year, meanwhile watch Cassava Sciences, Inc. stock price chart and keep track of the current situation with SAVA news and stock market news.
What is Abbvie stock price prediction for 2024? ›
According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024.
Is SAVA a good stock to buy? ›
The consensus among 2 Wall Street analysts covering (NASDAQ: SAVA) stock is to Strong Buy SAVA stock.
What is the potential of cassava production? ›
Overall, from the total output of 59.5 million metric tonnes of cassava produced in the country based on 2018 estimates, Nigeria has the economic potential to generate revenues of $427.3 million from domestic value-addition and derive income of $2.98 billion in agricultural exports of cassava.
Why is Cassava Sciences stock dropping? ›
Shares of Alzheimer's drug developer Cassava Sciences tumbled following the indictment of a medical professor who advised the company. The Justice Department said on Friday that City University of New York School of Medicine Professor Hoau-Yan Wang was indicted on charges related to obtaining federal research grants.